secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001372514-25-000050
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora grants Senju exclusive option for KIO-301 in Asia; $1.25M upfront, up to $110M milestones plus royalties
--------------------------------------------------------------------------------

- Immediate $1.25M option payment; if exercised, mid-single-digit million upfront and up to $110M in development, regulatory, and commercial milestones.
- Tiered royalties from high single-digit to high teen percent on net sales; territory covers Japan, China, and other key Asian countries.
- Option exercisable after topline data from ongoing ABACUS-2 Phase 2 trial; Senju to collaborate with Théa, Kiora's ex-Asia partner.
- Combined deal value with Théa (2024) and Senju exceeds $400M plus royalties; cash runway extended into late 2027.
- KIO-301 is a molecular photoswitch for retinitis pigmentosa and other inherited retinal diseases, currently in Phase 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251425000050/0001372514-25-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251425000050/kprx-20250530.htm
  HTML page:      https://secwatch.observer/filing/0001372514-25-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer